GlaxoSmithKline anticipates five new products in 2007

GlaxoSmithKline expects to launch five new products this year, the drugmaker told investors today as it announced its 2006 financial results. “We now have over 30 significant product opportunities in phase III development or registration, including five major new products planned for launch this year,” CEO JP Garnier said in a statement. Glaxo plans to launch Tykerb for breast cancer during the first half of 2007; Allermist/Avamys for allergic rhinitis, also during the first half the year; Coreg for heart conditions during the first quarter; and Trexima for migraine during the second half of 2007. The firm also expects to file for approval for its cervical cancer vaccine Cervarix in April.